The Mechanism of Action of Praziquantel: Can New Drugs Exploit Similar Mechanisms?

Author(s): Charlotte M. Thomas, David J. Timson*

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 5 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Praziquantel (PZQ) is the drug of choice for treating infection with worms from the genus Schistosoma. The drug is effective, cheap and has few side effects. However, despite its use in millions of patients for over 40 years its molecular mechanism of action remains elusive. Early studies demonstrated that PZQ disrupts calcium ion homeostasis in the worm and the current consensus is that it antagonises voltage-gated calcium channels. It is hypothesised that disruption of these channels results in uncontrolled calcium ion influx leading to uncontrolled muscle contraction and paralysis. However, other experimental studies have suggested a role for myosin regulatory light chains and adenosine uptake in the drug’s mechanism of action. Assuming voltage-gated calcium channels do represent the main molecular target of PZQ, the precise binding site for the drug remains to be identified. Unlike other commonly used anti-parasitic drugs, there are few definitive reports of resistance to PZQ in the literature. The lack of knowledge about PZQ’s molecular mechanism(s) undermines our ability to predict how resistance might arise and also hinder our attempts to develop alternative antischistosomal drugs which exploit the same target(s). Some PZQ derivatives have been identified which also kill or paralyse schistosomes in culture. However, none of these are in widespread clinical use. There is a pressing need for fundamental research into the molecular mechanism( s) of action of PZQ. Such research would enable new avenues for antischsistosomal drug discovery.

Keywords: Praziquantel, schistosomiasis, voltage-gated calcium channels, neglected tropical disease, calcium signalling, drug mechanism.

[1]
Utzinger, J.; Becker, S.L.; Knopp, S.; Blum, J.; Neumayr, A.L.; Keiser, J.; Hatz, C.F. Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med. Wkly., 2012, 142 w13727
[http://dx.doi.org/10.4414/smw.2012.13727] [PMID: 23180107]
[2]
Utzinger, J.; Raso, G.; Brooker, S.; De Savigny, D.; Tanner, M.; Ornbjerg, N.; Singer, B.H.; N’goran, E.K. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology, 2009, 136(13), 1859-1874.
[http://dx.doi.org/10.1017/S0031182009991600] [PMID: 19906318]
[3]
Gryseels, B.; Polman, K.; Clerinx, J.; Kestens, L. Human schistosomiasis. Lancet, 2006, 368(9541), 1106-1118.
[http://dx.doi.org/10.1016/S0140-6736(06)69440-3] [PMID: 16997665]
[4]
Steinmann, P.; Keiser, J.; Bos, R.; Tanner, M.; Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis., 2006, 6(7), 411-425.
[http://dx.doi.org/10.1016/S1473-3099(06)70521-7] [PMID: 16790382]
[5]
van der Werf, M.J.; de Vlas, S.J.; Brooker, S.; Looman, C.W.; Nagelkerke, N.J.; Habbema, J.D.; Engels, D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop., 2003, 86(2-3), 125-139.
[http://dx.doi.org/10.1016/S0001-706X(03)00029-9] [PMID: 12745133]
[6]
Lengeler, C.; Utzinger, J.; Tanner, M. Questionnaires for rapid screening of schistosomiasis in sub-Saharan Africa. Bull. World Health Organ., 2002, 80(3), 235-242.
[PMID: 11984610]
[7]
Hotez, P.J. The neglected tropical diseases and their devastating health and economic impact on the member nations of the organisation of the Islamic Conference. PLoS Negl. Trop. Dis., 2009, 3(10) e539
[http://dx.doi.org/10.1371/journal.pntd.0000539] [PMID: 19859530]
[8]
Hotez, P.J.; Kamath, A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl. Trop. Dis., 2009, 3(8) e412
[http://dx.doi.org/10.1371/journal.pntd.0000412] [PMID: 19707588]
[9]
Hotez, P.J.; Woc-Colburn, L.; Bottazzi, M.E. Neglected tropical diseases in Central America and Panama: review of their prevalence, populations at risk and impact on regional development. Int. J. Parasitol., 2014, 44(9), 597-603.
[http://dx.doi.org/10.1016/j.ijpara.2014.04.001] [PMID: 24846528]
[10]
Blair, D.; Campos, A.; Cummings, M.P.; Laclette, J.P. Evolutionary biology of parasitic platyhelminths: The role of molecular phylogenetics. Parasitol. Today (Regul. Ed.), 1996, 12(2), 66-71.
[http://dx.doi.org/10.1016/0169-4758(96)80657-0] [PMID: 15275257]
[11]
Olson, P.D.; Cribb, T.H.; Tkach, V.V.; Bray, R.A.; Littlewood, D.T. Phylogeny and classification of the Digenea (Platyhelminthes: Trematoda). Int. J. Parasitol., 2003, 33(7), 733-755.
[http://dx.doi.org/10.1016/S0020-7519(03)00049-3] [PMID: 12814653]
[12]
Walker, A.J. Insights into the functional biology of schistosomes. Parasit. Vectors, 2011, 4, 203.
[http://dx.doi.org/10.1186/1756-3305-4-203] [PMID: 22013990]
[13]
Colley, D.G.; Bustinduy, A.L.; Secor, W.E.; King, C.H. Human schistosomiasis. Lancet, 2014, 383(9936), 2253-2264.
[http://dx.doi.org/10.1016/S0140-6736(13)61949-2] [PMID: 24698483]
[14]
He, Y.X.; Chen, L.; Ramaswamy, K. Schistosoma mansoni, S. haematobium, and S. japonicum: early events associated with penetration and migration of schistosomula through human skin. Exp. Parasitol., 2002, 102(2), 99-108.
[http://dx.doi.org/10.1016/S0014-4894(03)00024-9] [PMID: 12706745]
[15]
Dean, D.A.; Mangold, B.L. Evidence that both normal and immune elimination of Schistosoma mansoni take place at the lung stage of migration prior to parasite death. Am. J. Trop. Med. Hyg., 1992, 47(2), 238-248.
[http://dx.doi.org/10.4269/ajtmh.1992.47.238] [PMID: 1503191]
[16]
Collins, J.J., III; King, R.S.; Cogswell, A.; Williams, D.L.; Newmark, P.A. An atlas for Schistosoma mansoni organs and life-cycle stages using cell type-specific markers and confocal microscopy. PLoS Negl. Trop. Dis., 2011, 5(3) e1009
[http://dx.doi.org/10.1371/journal.pntd.0001009] [PMID: 21408085]
[17]
Burke, M.L.; Jones, M.K.; Gobert, G.N.; Li, Y.S.; Ellis, M.K.; McManus, D.P. Immunopathogenesis of human schistosomiasis. Parasite Immunol., 2009, 31(4), 163-176.
[http://dx.doi.org/10.1111/j.1365-3024.2009.01098.x] [PMID: 19292768]
[18]
Ross, A.G.; Vickers, D.; Olds, G.R.; Shah, S.M.; McManus, D.P. Katayama syndrome. Lancet Infect. Dis., 2007, 7(3), 218-224.
[http://dx.doi.org/10.1016/S1473-3099(07)70053-1] [PMID: 17317603]
[19]
Ross, A.G.; McManus, D.P.; Farrar, J.; Hunstman, R.J.; Gray, D.J.; Li, Y.S. Neuroschistosomiasis. J. Neurol., 2012, 259(1), 22-32.
[http://dx.doi.org/10.1007/s00415-011-6133-7] [PMID: 21674195]
[20]
Schwartz, D.A. Helminths in the induction of cancer II. Schistosoma haematobium and bladder cancer. Trop. Geogr. Med., 1981, 33(1), 1-7.
[PMID: 7018036]
[21]
Pax, R.; Bennett, J.L.; Fetterer, R. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch. Pharmacol., 1978, 304(3), 309-315.
[http://dx.doi.org/10.1007/BF00507974] [PMID: 714190]
[22]
Coles, G.C. The effect of praziquantel on Schistosoma mansoni. J. Helminthol., 1979, 53(1), 31-33.
[http://dx.doi.org/10.1017/S0022149X00005691] [PMID: 458128]
[23]
Cioli, D.; Pica-Mattoccia, L.; Basso, A.; Guidi, A. Schistosomiasis control: praziquantel forever? Mol. Biochem. Parasitol., 2014, 195(1), 23-29.
[http://dx.doi.org/10.1016/j.molbiopara.2014.06.002] [PMID: 24955523]
[24]
Cioli, D.; Pica-Mattoccia, L. Praziquantel. Parasitol. Res., 2003, 90(Suppl. 1), S3-S9.
[http://dx.doi.org/10.1007/s00436-002-0751-z] [PMID: 12811543]
[25]
Doenhoff, M.J.; Cioli, D.; Utzinger, J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis., 2008, 21(6), 659-667.
[http://dx.doi.org/10.1097/QCO.0b013e328318978f] [PMID: 18978535]
[26]
da Silva, V.B.R.; Campos, B.R.K.L.; de Oliveira, J.F.; Decout, J.L.; do Carmo Alves de Lima, M. Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine. Bioorg. Med. Chem., 2017, 25(13), 3259-3277.
[http://dx.doi.org/10.1016/j.bmc.2017.04.031] [PMID: 28495384]
[27]
Cioli, D.; Pica-Mattoccia, L.; Archer, S. Antischistosomal drugs: past, present and future? Pharmacol. Ther., 1995, 68(1), 35-85.
[http://dx.doi.org/10.1016/0163-7258(95)00026-7] [PMID: 8604437]
[28]
Foster, R. A review of clinical experience with oxamniquine. Trans. R. Soc. Trop. Med. Hyg., 1987, 81(1), 55-59.
[http://dx.doi.org/10.1016/0035-9203(87)90282-3] [PMID: 3127959]
[29]
Pica-Mattoccia, L.; Cioli, D. Studies on the mode of action of oxamniquine and related schistosomicidal drugs. Am. J. Trop. Med. Hyg., 1985, 34(1), 112-118.
[http://dx.doi.org/10.4269/ajtmh.1985.34.112] [PMID: 3838223]
[30]
Pica-Mattoccia, L.; Cioli, D.; Archer, S. Binding of oxamniquine to the DNA of schistosomes. Trans. R. Soc. Trop. Med. Hyg., 1989, 83(3), 373-376.
[http://dx.doi.org/10.1016/0035-9203(89)90508-7] [PMID: 2617584]
[31]
Pica-Mattoccia, L.; Carlini, D.; Guidi, A.; Cimica, V.; Vigorosi, F.; Cioli, D. The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase. Mem. Inst. Oswaldo Cruz, 2006, 101(Suppl. 1), 307-312.
[http://dx.doi.org/10.1590/S0074-02762006000900048] [PMID: 17308787]
[32]
Taylor, A.B.; Roberts, K.M.; Cao, X.; Clark, N.E.; Holloway, S.P.; Donati, E.; Polcaro, C.M.; Pica-Mattoccia, L.; Tarpley, R.S.; McHardy, S.F.; Cioli, D.; LoVerde, P.T.; Fitzpatrick, P.F.; Hart, P.J. Structural and enzymatic insights into species-specific resistance to schistosome parasite drug therapy. J. Biol. Chem., 2017, 292(27), 11154-11164.
[http://dx.doi.org/10.1074/jbc.M116.766527] [PMID: 28536265]
[33]
Chevalier, F.D.; Le Clec’h, W.; Eng, N.; Rugel, A.R.; Assis, R.R.; Oliveira, G.; Holloway, S.P.; Cao, X.; Hart, P.J.; LoVerde, P.T.; Anderson, T.J. Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population. Int. J. Parasitol., 2016, 46(7), 417-424.
[http://dx.doi.org/10.1016/j.ijpara.2016.03.006] [PMID: 27073078]
[34]
Chai, J.Y. Praziquantel treatment in trematode and cestode infections: an update. Infect. Chemother., 2013, 45(1), 32-43.
[http://dx.doi.org/10.3947/ic.2013.45.1.32] [PMID: 24265948]
[35]
Forwood, J.M.; Bubner, E.J.; Landos, M.; Deveney, M.R.; D’Antignana, T. Praziquantel delivery via moist pellets to treat monogenean parasites of yellowtail kingfish Seriola lalandi: efficacy and feed acceptance. Dis. Aquat. Organ., 2016, 121(3), 201-209.
[http://dx.doi.org/10.3354/dao03054] [PMID: 27786158]
[36]
Scala, A.; Urrai, G.; Varcasia, A.; Nicolussi, P.; Mulas, M.; Goddi, L.; Pipia, A.P.; Sanna, G.; Genchi, M.; Bandino, E. Acute visceral cysticercosis by Taenia hydatigena in lambs and treatment with praziquantel. J. Helminthol., 2016, 90(1), 113-116.
[http://dx.doi.org/10.1017/S0022149X14000601] [PMID: 25120032]
[37]
Jiang, B.; Zhou, X.N.; Zhang, H.B.; Tao, Y.; Huo, L.L.; Liu, N. Slow-release praziquantel for dogs: presentation of a new formulation for echinococcosis control. Infect. Dis. Poverty, 2017, 6(1), 140.
[http://dx.doi.org/10.1186/s40249-017-0357-4] [PMID: 28911334]
[38]
Qian, M.; Wei, L.; Hao, L.; Tang, S. Pharmacokinetics of new high-concentration and long-acting praziquantel oily suspensions after intramuscular administration in cattle. J. Vet. Pharmacol. Ther., 2017, 40(5), 454-458.
[http://dx.doi.org/10.1111/jvp.12378] [PMID: 27905117]
[39]
Thomas, A.; Dawson, M.R.; Ellis, H.; Stamper, M.A. Praziquantel degradation in marine aquarium water. PeerJ, 2016, 4e, 1857.
[http://dx.doi.org/10.7717/peerj.1857] [PMID: 27069797]
[40]
Smego, R.A., Jr; Sebanego, P. Treatment options for hepatic cystic echinococcosis. International journal of infectious diseases: IJID : official publication of the International Society for Infectious Diseases, 2005, 9(2), 69-76.
[http://dx.doi.org/10.1016/j.ijid.2004.08.001]
[41]
Farag, H.F.; Ragab, M.; Salem, A.; Sadek, N. A short note on praziquantel in human fascioliasis. J. Trop. Med. Hyg., 1986, 89(2), 79-80.
[PMID: 3773022]
[42]
Farid, Z.; Kamal, M.; Mansour, N. Praziquantel and Fasciola hepatica infection. Trans. R. Soc. Trop. Med. Hyg., 1989, 83(6), 813.
[http://dx.doi.org/10.1016/0035-9203(89)90339-8] [PMID: 2617651]
[43]
Patrick, D.M.; Isaac-Renton, J. Praziquantel failure in the treatment of Fasciola hepatica. Can. J. Infect. Dis., 1992, 3(1), 33-36.
[http://dx.doi.org/10.1155/1992/864093] [PMID: 22451761]
[44]
Sabah, A.A.; Fletcher, C.; Webbe, G.; Doenhoff, M.J. Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice. Exp. Parasitol., 1985, 60(3), 348-354.
[http://dx.doi.org/10.1016/0014-4894(85)90041-4] [PMID: 3935473]
[45]
Pica-Mattoccia, L.; Cioli, D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int. J. Parasitol., 2004, 34(4), 527-533.
[http://dx.doi.org/10.1016/j.ijpara.2003.12.003] [PMID: 15013742]
[46]
Botros, S.; Pica-Mattoccia, L.; William, S.; El-Lakkani, N.; Cioli, D. Effect of praziquantel on the immature stages of Schistosoma haematobium. Int. J. Parasitol., 2005, 35(13), 1453-1457.
[http://dx.doi.org/10.1016/j.ijpara.2005.05.002] [PMID: 16002073]
[47]
Olveda, D.U.; McManus, D.P.; Ross, A.G. Mass drug administration and the global control of schistosomiasis: successes, limitations and clinical outcomes. Curr. Opin. Infect. Dis., 2016, 29(6), 595-608.
[http://dx.doi.org/10.1097/QCO.0000000000000312] [PMID: 27584590]
[48]
Mutapi, F.; Maizels, R.; Fenwick, A.; Woolhouse, M. Human schistosomiasis in the post mass drug administration era. Lancet Infect. Dis., 2017, 17(2), e42-e48.
[http://dx.doi.org/10.1016/S1473-3099(16)30475-3] [PMID: 27988094]
[49]
Mitchell, K.M.; Mutapi, F.; Mduluza, T.; Midzi, N.; Savill, N.J.; Woolhouse, M.E. Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium. PLoS Negl. Trop. Dis., 2014, 8(7) e3059
[http://dx.doi.org/10.1371/journal.pntd.0003059] [PMID: 25079601]
[50]
French, M.D.; Churcher, T.S.; Gambhir, M.; Fenwick, A.; Webster, J.P.; Kabatereine, N.B.; Basáñez, M.G. Observed reductions in Schistosoma mansoni transmission from large-scale administration of praziquantel in Uganda: a mathematical modelling study. PLoS Negl. Trop. Dis., 2010, 4(11) e897
[http://dx.doi.org/10.1371/journal.pntd.0000897] [PMID: 21124888]
[51]
Humphries, D.; Nguyen, S.; Boakye, D.; Wilson, M.; Cappello, M. The promise and pitfalls of mass drug administration to control intestinal helminth infections. Curr. Opin. Infect. Dis., 2012, 25(5), 584-589.
[http://dx.doi.org/10.1097/QCO.0b013e328357e4cf] [PMID: 22903231]
[52]
Groll, E. Praziquantel. Adv. Pharmacol. Chemother., 1984, 20, 219-238.
[http://dx.doi.org/10.1016/S1054-3589(08)60268-9] [PMID: 6398968]
[53]
Andrews, P.; Thomas, H.; Pohlke, R.; Seubert, J. Praziquantel. Med. Res. Rev., 1983, 3(2), 147-200.
[http://dx.doi.org/10.1002/med.2610030204] [PMID: 6408323]
[54]
Leopold, G.; Ungethüm, W.; Groll, E.; Diekmann, H.W.; Nowak, H.; Wegner, D.H. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur. J. Clin. Pharmacol., 1978, 14(4), 281-291.
[http://dx.doi.org/10.1007/BF00560463] [PMID: 729622]
[55]
Davis, A.; Wegner, D.H. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull. World Health Organ., 1979, 57(5), 767-771.
[PMID: 317254]
[56]
Mehlhorn, H.; Becker, B.; Andrews, P.; Thomas, H.; Frenkel, J.K. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study. Arzneimittelforschung, 1981, 31(3a), 544-554.
[PMID: 7195245]
[57]
Liu, Y.H.; Qian, M.X.; Wang, X.G.; Jia, J.; Wang, Q.N.; Jiang, Y.F.; Wang, R.Q.; Yan, S.H.; Chen, B.Y.; Li, J.S. Comparative efficacy of praziquantel and its optic isomers in experimental therapy of Schistosomiasis japonica in rabbits. Chin. Med. J. (Engl.), 1986, 99(12), 935-940.
[PMID: 3105969]
[58]
Xiao, S.H.; Catto, B.A. Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J. Infect. Dis., 1989, 159(3), 589-592.
[http://dx.doi.org/10.1093/infdis/159.3.589] [PMID: 2915173]
[59]
Tanaka, M.; Ohmae, H.; Utsunomiya, H.; Nara, T.; Irie, Y.; Yasuraoka, K. A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice. Am. J. Trop. Med. Hyg., 1989, 41(2), 198-203.
[http://dx.doi.org/10.4269/ajtmh.1989.41.198] [PMID: 2505624]
[60]
Abdul-Ghani, R.; Loutfy, N.; el-Sahn, A.; Hassan, A. Current chemotherapy arsenal for Schistosomiasis mansoni: alternatives and challenges. Parasitol. Res., 2009, 104(5), 955-965.
[http://dx.doi.org/10.1007/s00436-009-1371-7] [PMID: 19255786]
[61]
Wu, M.H.; Wei, C.C.; Xu, Z.Y.; Yuan, H.C.; Lian, W.N.; Yang, Q.J.; Chen, M.; Jiang, Q.W.; Wang, C.Z.; Zhang, S.J. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of Schistosomiasis japonica. Am. J. Trop. Med. Hyg., 1991, 45(3), 345-349.
[http://dx.doi.org/10.4269/ajtmh.1991.45.345] [PMID: 1928569]
[62]
Meyer, T.; Sekljic, H.; Fuchs, S.; Bothe, H.; Schollmeyer, D.; Miculka, C. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl. Trop. Dis., 2009, 3(1) e357
[http://dx.doi.org/10.1371/journal.pntd.0000357] [PMID: 19159015]
[63]
Roszkowski, P.; Maurin, J.K.; Czarnocki, Z. Enantioselective synthesis of (R)-(−)-praziquantel (PZQ). Tetrahedron Asymmetry, 2006, 17(9), 1415-1419.
[http://dx.doi.org/10.1016/j.tetasy.2006.04.023]
[64]
Woelfle, M.; Seerden, J.P.; de Gooijer, J.; Pouwer, K.; Olliaro, P.; Todd, M.H. Resolution of praziquantel. PLoS Negl. Trop. Dis., 2011, 5(9) e1260
[http://dx.doi.org/10.1371/journal.pntd.0001260] [PMID: 21949890]
[65]
Liu, Y.; Wang, X.; Wang, J.K.; Ching, C.B. Structural characterization and enantioseparation of the chiral compound praziquantel. J. Pharm. Sci., 2004, 93(12), 3039-3046.
[http://dx.doi.org/10.1002/jps.20211] [PMID: 15514924]
[66]
Ching, C.B.; Lim, B.G.; Lee, E.J.D.; Ng, S.C. Preparative resolution of praziquantel enantiomers by simulated counter-current chromatography. J. Chromatogr. A, 1993, 634(2), 215-219.
[http://dx.doi.org/10.1016/0021-9673(93)83007-F]
[67]
Lim, B.G.; Ching, C.B.; Tan, R.B.H.; Ng, S.C. Recovery of (−)-praziquantel from racemic mixtures by continuous chromatography and crystallisation. Chem. Eng. Sci., 1995, 50(14), 2289-2298.
[http://dx.doi.org/10.1016/0009-2509(95)00082-G]
[68]
Lindenberg, M.; Kopp, S.; Dressman, J.B. Classification of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm., 2004, 58(2), 265-278.
[http://dx.doi.org/10.1016/j.ejpb.2004.03.001]
[69]
Passerini, N.; Albertini, B.; Perissutti, B.; Rodriguez, L. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int. J. Pharm., 2006, 318(1-2), 92-102.
[http://dx.doi.org/10.1016/j.ijpharm.2006.03.028] [PMID: 16697539]
[70]
Masimirembwa, C.M.; Hasler, J.A. Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem. Pharmacol., 1994, 48(9), 1779-1783.
[http://dx.doi.org/10.1016/0006-2952(94)90464-2] [PMID: 7980647]
[71]
Godawska-Matysik, A.; Kieć-Kononowicz, K. Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol. Pharm., 2006, 63(5), 381-385.
[PMID: 17357589]
[72]
Godawska-Matysik, A.; Pekala, E.; Kiec-Kononowicz, K. The research on biotransformation of praziquantel. Acta poloniae pharmaceutica, 2004, 61(Suppl.), 75-78.
[PMID: 15909947]
[73]
Castro, N.; Gonzàlez-Esquivel, D.; Medina, R.; Sotelo, J.; Jung, H. The influence of cimetidine on plasma levels of praziquantel after a single day therapeutic regimen. Proc. West. Pharmacol. Soc., 1997, 40, 33-34.
[PMID: 9436206]
[74]
Jung, H.; Medina, R.; Castro, N.; Corona, T.; Sotelo, J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob. Agents Chemother., 1997, 41(6), 1256-1259.
[http://dx.doi.org/10.1128/AAC.41.6.1256] [PMID: 9174180]
[75]
Castro, N.; Medina, R.; Sotelo, J.; Jung, H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother., 2000, 44(10), 2903-2904.
[http://dx.doi.org/10.1128/AAC.44.10.2903-2904.2000] [PMID: 10991886]
[76]
González-Esquivel, D.; Rivera, J.; Castro, N.; Yepez-Mulia, L.; Jung Cook, H. In vitro characterization of some biopharmaceutical properties of praziquantel. Int. J. Pharm., 2005, 295(1-2), 93-99.
[http://dx.doi.org/10.1016/j.ijpharm.2005.01.033] [PMID: 15847994]
[77]
Na-Bangchang, K.; Vanijanonta, S.; Karbwang, J. Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone. Southeast Asian J. Trop. Med. Public Health, 1995, 26(1), 120-123.
[PMID: 8525397]
[78]
Sotelo, J.; Jung, H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin. Pharmacokinet., 1998, 34(6), 503-515.
[http://dx.doi.org/10.2165/00003088-199834060-00006] [PMID: 9646011]
[79]
Chen, M.G.; Fu, S.; Hua, X.J.; Wu, H.M. A retrospective survey on side effects of praziquantel among 25,693 cases of Schistosomiasis japonica. Southeast Asian J. Trop. Med. Public Health, 1983, 14(4), 495-500.
[PMID: 6673126]
[80]
Greenberg, R.M. Are Ca2+ channels targets of praziquantel action? Int. J. Parasitol., 2005, 35(1), 1-9.
[http://dx.doi.org/10.1016/j.ijpara.2004.09.004] [PMID: 15619510]
[81]
Salvador-Recatalà, V.; Greenberg, R.M. Calcium channels of schistosomes: unresolved questions and unexpected answers. Wiley Interdiscip. Rev. Membr. Transp. Signal., 2012, 1(1), 85-93.
[http://dx.doi.org/10.1002/wmts.19] [PMID: 22347719]
[82]
Fetterer, R.H.; Pax, R.A.; Bennett, J.L. Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of Schistosoma mansoni. Eur. J. Pharmacol., 1980, 64(1), 31-38.
[http://dx.doi.org/10.1016/0014-2999(80)90366-0] [PMID: 7449814]
[83]
Becker, B.; Mehlhorn, H.; Andrews, P.; Thomas, H.; Eckert, J. Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z. Parasitenkd., 1980, 63(2), 113-128.
[http://dx.doi.org/10.1007/BF00927527] [PMID: 7456640]
[84]
Dalton, J.P.; Skelly, P.; Halton, D.W. Role of the tegument and gut in nutrient uptake by parasitic platyhelminths. Can. J. Zool., 2004, 82(2), 211-232.
[http://dx.doi.org/10.1139/z03-213]
[85]
Wolde Mussie, E.; Vande Waa, J.; Pax, R.A.; Fetterer, R.; Bennett, J.L. Schistosoma mansoni: calcium efflux and effects of calcium-free media on responses of the adult male musculature to praziquantel and other agents inducing contraction. Exp. Parasitol., 1982, 53(2), 270-278.
[http://dx.doi.org/10.1016/0014-4894(82)90069-8] [PMID: 7060707]
[86]
Harnett, W.; Kusel, J.R. Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro. Parasitology, 1986, 93(Pt 2), 401-405.
[http://dx.doi.org/10.1017/S0031182000051568] [PMID: 2431374]
[87]
Mehlhorn, H.; Kojima, S.; Rim, H.J.; Ruenwongsa, P.; Andrews, P.; Thomas, H.; Bunnag, B. Ultrastructural investigations on the effects of praziquantel on human trematodes from Asia: Clonorchis sinensis, Metagonimus yokogawai, Opisthorchis viverrini, Paragonimus westermani and Schistosoma japonicum. Arzneimittelforschung, 1983, 33(1), 91-98.
[PMID: 6338885]
[88]
Becker, B.; Mehlhorn, H.; Andrews, P.; Thomas, H. Ultrastructural investigations on the effect of praziquantel on the tegument of five species of cestodes. Z. Parasitenkd., 1981, 64(3), 257-269.
[http://dx.doi.org/10.1007/BF00927373] [PMID: 7222923]
[89]
Blair, K.L.; Bennett, J.L.; Pax, R.A. Praziquantel: physiological evidence for its site(s) of action in magnesium-paralysed Schistosoma mansoni. Parasitology, 1992, 104(Pt 1), 59-66.
[http://dx.doi.org/10.1017/S0031182000060807] [PMID: 1614741]
[90]
Dolphin, A.C. Beta subunits of voltage-gated calcium channels. J. Bioenerg. Biomembr., 2003, 35(6), 599-620.
[http://dx.doi.org/10.1023/B:JOBB.0000008026.37790.5a] [PMID: 15000522]
[91]
Catterall, W.A. Voltage-gated calcium channels. Cold Spring Harb. Perspect. Biol., 2011, 3(8) a003947
[http://dx.doi.org/10.1101/cshperspect.a003947] [PMID: 21746798]
[92]
Minor, D.L., Jr; Findeisen, F. Progress in the structural understanding of voltage-gated calcium channel (CaV) function and modulation. Channels (Austin), 2010, 4(6), 459-474.
[http://dx.doi.org/10.4161/chan.4.6.12867] [PMID: 21139419]
[93]
Kim, E.Y.; Rumpf, C.H.; Van Petegem, F.; Arant, R.J.; Findeisen, F.; Cooley, E.S.; Isacoff, E.Y.; Minor, D.L., Jr Multiple C-terminal tail Ca(2+)/CaMs regulate Ca(V)1.2 function but do not mediate channel dimerization. EMBO J., 2010, 29(23), 3924-3938.
[http://dx.doi.org/10.1038/emboj.2010.260] [PMID: 20953164]
[94]
Perez-Reyes, E. Molecular characterization of a novel family of low voltage-activated, T-type, calcium channels. J. Bioenerg. Biomembr., 1998, 30(4), 313-318.
[http://dx.doi.org/10.1023/A:1021981420839] [PMID: 9758328]
[95]
Peterson, B.Z.; DeMaria, C.D.; Adelman, J.P.; Yue, D.T. Calmodulin is the Ca2+ sensor for Ca2+ -dependent inactivation of L-type calcium channels. Neuron, 1999, 22(3), 549-558.
[http://dx.doi.org/10.1016/S0896-6273(00)80709-6] [PMID: 10197534]
[96]
Erickson, M.G.; Alseikhan, B.A.; Peterson, B.Z.; Yue, D.T. Preassociation of calmodulin with voltage-gated Ca(2+) channels revealed by FRET in single living cells. Neuron, 2001, 31(6), 973-985.
[http://dx.doi.org/10.1016/S0896-6273(01)00438-X] [PMID: 11580897]
[97]
Pitt, G.S.; Zühlke, R.D.; Hudmon, A.; Schulman, H.; Reuter, H.; Tsien, R.W. Molecular basis of calmodulin tethering and Ca2+-dependent inactivation of L-type Ca2+ channels. J. Biol. Chem., 2001, 276(33), 30794-30802.
[http://dx.doi.org/10.1074/jbc.M104959200] [PMID: 11408490]
[98]
Zühlke, R.D.; Pitt, G.S.; Deisseroth, K.; Tsien, R.W.; Reuter, H. Calmodulin supports both inactivation and facilitation of L-type calcium channels. Nature, 1999, 399(6732), 159-162.
[http://dx.doi.org/10.1038/20200] [PMID: 10335846]
[99]
Kohn, A.B.; Anderson, P.A.; Roberts-Misterly, J.M.; Greenberg, R.M. Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J. Biol. Chem., 2001, 276(40), 36873-36876.
[http://dx.doi.org/10.1074/jbc.C100273200] [PMID: 11500482]
[100]
Kohn, A.B.; Roberts-Misterly, J.M.; Anderson, P.A.; Greenberg, R.M. Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel. Int. J. Parasitol., 2003, 33(12), 1303-1308.
[http://dx.doi.org/10.1016/S0020-7519(03)00209-1] [PMID: 14527513]
[101]
Kohn, A.B.; Roberts-Misterly, J.M.; Anderson, P.A.; Khan, N.; Greenberg, R.M. Specific sites in the beta interaction domain of a schistosome Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel. Parasitology, 2003, 127(Pt 4), 349-356.
[http://dx.doi.org/10.1017/S003118200300386X] [PMID: 14636021]
[102]
Cupit, P.M.; Cunningham, C. What is the mechanism of action of praziquantel and how might resistance strike? Future Med. Chem., 2015, 7(6), 701-705.
[http://dx.doi.org/10.4155/fmc.15.11] [PMID: 25996063]
[103]
Chen, Y.H.; Li, M.H.; Zhang, Y.; He, L.L.; Yamada, Y.; Fitzmaurice, A.; Shen, Y.; Zhang, H.; Tong, L.; Yang, J. Structural basis of the alpha1-beta subunit interaction of voltage-gated Ca2+ channels. Nature, 2004, 429(6992), 675-680.
[http://dx.doi.org/10.1038/nature02641] [PMID: 15170217]
[104]
Valle, C.; Troiani, A.R.; Festucci, A.; Pica-Mattoccia, L.; Liberti, P.; Wolstenholme, A.; Francklow, K.; Doenhoff, M.J.; Cioli, D. Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol. Biochem. Parasitol., 2003, 130(2), 111-115.
[http://dx.doi.org/10.1016/S0166-6851(03)00171-3] [PMID: 12946847]
[105]
Aragon, A.D.; Imani, R.A.; Blackburn, V.R.; Cupit, P.M.; Melman, S.D.; Goronga, T.; Webb, T.; Loker, E.S.; Cunningham, C. Towards an understanding of the mechanism of action of praziquantel. Mol. Biochem. Parasitol., 2009, 164(1), 57-65.
[http://dx.doi.org/10.1016/j.molbiopara.2008.11.007] [PMID: 19100294]
[106]
Pica-Mattoccia, L.; Orsini, T.; Basso, A.; Festucci, A.; Liberti, P.; Guidi, A.; Marcatto-Maggi, A.L.; Nobre-Santana, S.; Troiani, A.R.; Cioli, D.; Valle, C. Schistosoma mansoni: lack of correlation between praziquantel-induced intra-worm calcium influx and parasite death. Exp. Parasitol., 2008, 119(3), 332-335.
[http://dx.doi.org/10.1016/j.exppara.2008.03.012] [PMID: 18456260 ]
[107]
Agata, K.; Watanabe, K. Molecular and cellular aspects of planarian regeneration. Semin. Cell Dev. Biol., 1999, 10(4), 377-383.
[http://dx.doi.org/10.1006/scdb.1999.0324] [PMID: 10497094]
[108]
Nogi, T.; Zhang, D.; Chan, J.D.; Marchant, J.S. A novel biological activity of praziquantel requiring voltage-operated Ca2+ channel beta subunits: subversion of flatworm regenerative polarity. PLoS Negl. Trop. Dis., 2009, 3(6) e464
[http://dx.doi.org/10.1371/journal.pntd.0000464] [PMID: 19554083]
[109]
Zhang, D.; Chan, J.D.; Nogi, T.; Marchant, J.S. Opposing roles of voltage-gated Ca2+ channels in neuronal control of regenerative patterning. J. Neurosci., 2011, 31(44), 15983-15995.
[http://dx.doi.org/10.1523/JNEUROSCI.3029-11.2011] [PMID: 22049441]
[110]
Rink, J.C.; Gurley, K.A.; Elliott, S.A.; Sánchez Alvarado, A. Planarian Hh signaling regulates regeneration polarity and links Hh pathway evolution to cilia. Science, 2009, 326(5958), 1406-1410.
[http://dx.doi.org/10.1126/science.1178712] [PMID: 19933103]
[111]
Chan, J.D.; Zarowiecki, M.; Marchant, J.S. Ca2+ channels and praziquantel: a view from the free world. Parasitol. Int., 2013, 62(6), 619-628.
[http://dx.doi.org/10.1016/j.parint.2012.12.001] [PMID: 23246536]
[112]
Church, J.; Zsotér, T.T. Calcium antagonistic drugs. Mechanism of action. Can. J. Physiol. Pharmacol., 1980, 58(3), 254-264.
[http://dx.doi.org/10.1139/y80-044] [PMID: 7378928]
[113]
Curtis, T.M.; Scholfield, C.N. Nifedipine blocks Ca2+ store refilling through a pathway not involving L-type Ca2+ channels in rabbit arteriolar smooth muscle. J. Physiol., 2001, 532(Pt 3), 609-623.
[http://dx.doi.org/10.1111/j.1469-7793.2001.0609e.x] [PMID: 11313433]
[114]
Triggle, D.J. 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell. Mol. Neurobiol., 2003, 23(3), 293-303.
[http://dx.doi.org/10.1023/A:1023632419813] [PMID: 12825828]
[115]
Silva-Moraes, V.; Couto, F.F.; Vasconcelos, M.M.; Araújo, N.; Coelho, P.M.; Katz, N.; Grenfell, R.F. Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms. Mem. Inst. Oswaldo Cruz, 2013, 108(5), 600-604.
[http://dx.doi.org/10.1590/0074-0276108052013011] [PMID: 23903976]
[116]
Novozhilova, E.; Kimber, M.J.; Qian, H.; McVeigh, P.; Robertson, A.P.; Zamanian, M.; Maule, A.G.; Day, T.A. FMRFamide-like peptides (FLPs) enhance voltage-gated calcium currents to elicit muscle contraction in the human parasite Schistosoma mansoni. PLoS Negl. Trop. Dis., 2010, 4(8) e790
[http://dx.doi.org/10.1371/journal.pntd.0000790] [PMID: 20706630]
[117]
Katsumata, T.; Kohno, S.; Yamaguchi, K.; Hara, K.; Aoki, Y. Hatching of Schistosoma mansoni eggs is a Ca2+/calmodulin-dependent process. Parasitol. Res., 1989, 76(1), 90-91.
[http://dx.doi.org/10.1007/BF00931079] [PMID: 2622901]
[118]
Senft, A.; Gibler, W.; Guterman, J. Influence of calcium‐ perturbing agents on schistosomes: Comparison of effects of praziquantel and verapamil on worm tegument. J. Exp. Zool. Part A. Ecol. Genet. Physiol., 1986, 239(1), 25-36.
[http://dx.doi.org/10.1002/jez.1402390105]
[119]
Taft, A.S.; Yoshino, T.P. Cloning and functional characterization of two calmodulin genes during larval development in the parasitic flatworm Schistosoma mansoni. J. Parasitol., 2011, 97(1), 72-81.
[http://dx.doi.org/10.1645/GE-2586.1] [PMID: 21348610]
[120]
Thompson, D.P.; Chen, G.Z.; Sample, A.K.; Semeyn, D.R.; Bennett, J.L. Calmodulin: biochemical, physiological, and morphological effects on Schistosoma mansoni. Am. J. Physiol., 1986, 251(6 Pt 2), R1051-R1058.
[http://dx.doi.org/10.1152/ajpregu.1986.251.6.R1051] [PMID: 3024507]
[121]
Ben-Johny, M.; Yue, D.T. Calmodulin regulation (calmodulation) of voltage-gated calcium channels. J. Gen. Physiol., 2014, 143(6), 679-692.
[http://dx.doi.org/10.1085/jgp.201311153] [PMID: 24863929]
[122]
Berriman, M.; Haas, B.J.; LoVerde, P.T.; Wilson, R.A.; Dillon, G.P.; Cerqueira, G.C.; Mashiyama, S.T.; Al-Lazikani, B.; Andrade, L.F.; Ashton, P.D.; Aslett, M.A.; Bartholomeu, D.C.; Blandin, G.; Caffrey, C.R.; Coghlan, A.; Coulson, R.; Day, T.A.; Delcher, A.; DeMarco, R.; Djikeng, A.; Eyre, T.; Gamble, J.A.; Ghedin, E.; Gu, Y.; Hertz-Fowler, C.; Hirai, H.; Hirai, Y.; Houston, R.; Ivens, A.; Johnston, D.A.; Lacerda, D.; Macedo, C.D.; McVeigh, P.; Ning, Z.; Oliveira, G.; Overington, J.P.; Parkhill, J.; Pertea, M.; Pierce, R.J.; Protasio, A.V.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Sajid, M.; Salzberg, S.L.; Stanke, M.; Tivey, A.R.; White, O.; Williams, D.L.; Wortman, J.; Wu, W.; Zamanian, M.; Zerlotini, A.; Fraser-Liggett, C.M.; Barrell, B.G.; El-Sayed, N.M. The genome of the blood fluke Schistosoma mansoni. Nature, 2009, 460(7253), 352-358.
[http://dx.doi.org/10.1038/nature08160] [PMID: 19606141]
[123]
Kohn, A.B.; Lea, J.; Roberts-Misterly, J.M.; Anderson, P.A.; Greenberg, R.M. Structure of three high voltage-activated calcium channel alpha1 subunits from Schistosoma mansoni. Parasitology, 2001, 123(Pt 5), 489-497.
[http://dx.doi.org/10.1017/S0031182001008691] [PMID: 11719960]
[124]
Thomas, C.M.; Timson, D.J. A mysterious family of calcium-binding proteins from parasitic worms. Biochem. Soc. Trans., 2016, 44(4), 1005-1010.
[http://dx.doi.org/10.1042/BST20150270] [PMID: 27528745]
[125]
Fitzsimmons, C.M.; Jones, F.M.; Stearn, A.; Chalmers, I.W.; Hoffmann, K.F.; Wawrzyniak, J.; Wilson, S.; Kabatereine, N.B.; Dunne, D.W. The Schistosoma mansoni tegumental-allergen-like (TAL) protein family: influence of developmental expression on human IgE responses. PLoS Negl. Trop. Dis., 2012, 6(4) e1593
[http://dx.doi.org/10.1371/journal.pntd.0001593] [PMID: 22509417]
[126]
Thomas, C.M.; Fitzsimmons, C.M.; Dunne, D.W.; Timson, D.J. Comparative biochemical analysis of three members of the Schistosoma mansoni TAL family: differences in ion and drug binding properties. Biochimie, 2015, 108, 40-47.
[http://dx.doi.org/10.1016/j.biochi.2014.10.015] [PMID: 25447146]
[127]
Hoffmann, K.F.; Strand, M. Molecular characterization of a 20.8-kDa Schistosoma mansoni antigen. Sequence similarity to tegumental associated antigens and dynein light chains. J. Biol. Chem., 1997, 272(23), 14509-14515.
[http://dx.doi.org/10.1074/jbc.272.23.14509] [PMID: 9169407]
[128]
Carson, J.; Thomas, C.M.; McGinty, A.; Takata, G.; Timson, D.J. The tegumental allergen-like proteins of Schistosoma mansoni: a biochemical study of SmTAL4-TAL13. Mol. Biochem. Parasitol., 2018, 221, 14-22.
[http://dx.doi.org/10.1016/j.molbiopara.2018.02.002] [PMID: 29453993]
[129]
Greenberg, R.M. Ion channels and drug transporters as targets for anthelmintics. Curr. Clin. Microbiol. Rep., 2014, 1(3-4), 51-60.
[http://dx.doi.org/10.1007/s40588-014-0007-6] [PMID: 25554739]
[130]
Pica-Mattoccia, L.; Valle, C.; Basso, A.; Troiani, A.R.; Vigorosi, F.; Liberti, P.; Festucci, A.; Cioli, D. Cytochalasin D abolishes the schistosomicidal activity of praziquantel. Exp. Parasitol., 2007, 115(4), 344-351.
[http://dx.doi.org/10.1016/j.exppara.2006.09.017] [PMID: 17083933]
[131]
Tallima, H.; El Ridi, R. Praziquantel binds Schistosoma mansoni adult worm actin. Int. J. Antimicrob. Agents, 2007, 29(5), 570-575.
[http://dx.doi.org/10.1016/j.ijantimicag.2006.12.018] [PMID: 17341443]
[132]
Troiani, A.R.; Pica-Mattoccia, L.; Valle, C.; Cioli, D.; Mignogna, G.; Ronketti, F.; Todd, M. Is actin the praziquantel receptor? Int. J. Antimicrob. Agents, 2007, 30(3), 280-281.
[http://dx.doi.org/10.1016/j.ijantimicag.2007.05.004] [PMID: 17618088]
[133]
Angelucci, F.; Basso, A.; Bellelli, A.; Brunori, M.; Pica Mattoccia, L.; Valle, C. The anti-schistosomal drug praziquantel is an adenosine antagonist. Parasitology, 2007, 134(Pt 9), 1215-1221.
[http://dx.doi.org/10.1017/S0031182007002600] [PMID: 17428352]
[134]
Gnanasekar, M.; Salunkhe, A.M.; Mallia, A.K.; He, Y.X.; Kalyanasundaram, R. Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni. Antimicrob. Agents Chemother., 2009, 53(3), 1054-1060.
[http://dx.doi.org/10.1128/AAC.01222-08] [PMID: 19104008]
[135]
Rayment, I.; Rypniewski, W.R.; Schmidt-Bäse, K.; Smith, R.; Tomchick, D.R.; Benning, M.M.; Winkelmann, D.A.; Wesenberg, G.; Holden, H.M. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science, 1993, 261(5117), 50-58.
[http://dx.doi.org/10.1126/science.8316857] [PMID: 8316857]
[136]
Scholey, J.M.; Taylor, K.A.; Kendrick-Jones, J. The role of myosin light chains in regulating actin-myosin interaction. Biochimie, 1981, 63(4), 255-271.
[http://dx.doi.org/10.1016/S0300-9084(81)80115-0] [PMID: 7013829]
[137]
Zhang, Y.; Moreland, S.; Moreland, R.S. Regulation of vascular smooth muscle contraction: myosin light chain phosphorylation dependent and independent pathways. Can. J. Physiol. Pharmacol., 1994, 72(11), 1386-1391.
[http://dx.doi.org/10.1139/y94-200] [PMID: 7767883]
[138]
McTigue, M.A.; Williams, D.R.; Tainer, J.A. Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel. J. Mol. Biol., 1995, 246(1), 21-27.
[http://dx.doi.org/10.1006/jmbi.1994.0061] [PMID: 7853399]
[139]
Milhon, J.L.; Thiboldeaux, R.L.; Glowac, K.; Tracy, J.W. Schistosoma japonicum GSH S-transferase Sj26 is not the molecular target of praziquantel action. Exp. Parasitol., 1997, 87(3), 268-274.
[http://dx.doi.org/10.1006/expr.1997.4231] [PMID: 9371093]
[140]
Chan, J.D.; Cupit, P.M.; Gunaratne, G.S.; McCorvy, J.D.; Yang, Y.; Stoltz, K.; Webb, T.R.; Dosa, P.I.; Roth, B.L.; Abagyan, R.; Cunningham, C.; Marchant, J.S. The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand. Nat. Commun., 2017, 8(1), 1910.
[http://dx.doi.org/10.1038/s41467-017-02084-0] [PMID: 29208933]
[141]
Calama, E.; Morán, A.; Ortiz de Urbina, A.V.; Martín, M.L.; San Román, L. Vasoconstrictor responses to 5-hydroxytryptamine in the autoperfused hindquarters of spontaneously hypertensive rats. Pharmacology, 2004, 71(2), 66-72.
[http://dx.doi.org/10.1159/000076942] [PMID: 15118345]
[142]
Doenhoff, M.J.; Modha, J.; Lambertucci, J.R. Anti-schistosome chemotherapy enhanced by antibodies specific for a parasite esterase. Immunology, 1988, 65(4), 507-510.
[PMID: 3146547]
[143]
Hall, T.M.; Joseph, G.T.; Strand, M. Schistosoma mansoni: molecular cloning and sequencing of the 200-kDa chemotherapeutic target antigen. Exp. Parasitol., 1995, 80(2), 242-249.
[http://dx.doi.org/10.1006/expr.1995.1030] [PMID: 7534724]
[144]
Zhang, Z.; Xu, H.; Gan, W.; Zeng, S.; Hu, X. Schistosoma japonicum calcium-binding tegumental protein SjTP22.4 immunization confers praziquantel schistosomulumicide and antifecundity effect in mice. Vaccine, 2012, 30(34), 5141-5150.
[http://dx.doi.org/10.1016/j.vaccine.2012.05.056] [PMID: 22683520]
[145]
Fallon, P.G.; Doenhoff, M.J. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg., 1994, 51(1), 83-88.
[http://dx.doi.org/10.4269/ajtmh.1994.51.83] [PMID: 8059919]
[146]
Brennan, G.P.; Fairweather, I.; Trudgett, A.; Hoey, E. McCoy; McConville, M.; Meaney, M.; Robinson, M.; McFerran, N.; Ryan, L.; Lanusse, C.; Mottier, L.; Alvarez, L.; Solana, H.; Virkel, G.; Brophy, P.M. Understanding triclabendazole resistance. Exp. Mol. Pathol., 2007, 82(2), 104-109.
[http://dx.doi.org/10.1016/j.yexmp.2007.01.009] [PMID: 17398281]
[147]
Wilkinson, R.; Law, C.J.; Hoey, E.M.; Fairweather, I.; Brennan, G.P.; Trudgett, A. An amino acid substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible populations. Mol. Biochem. Parasitol., 2012, 186(1), 69-72.
[http://dx.doi.org/10.1016/j.molbiopara.2012.08.008] [PMID: 22982092]
[148]
Jabbar, A.; Iqbal, Z.; Kerboeuf, D.; Muhammad, G.; Khan, M.N.; Afaq, M. Anthelmintic resistance: the state of play revisited. Life Sci., 2006, 79(26), 2413-2431.
[http://dx.doi.org/10.1016/j.lfs.2006.08.010] [PMID: 16979192]
[149]
Greenberg, R.M. New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology, 2013, 140(12), 1534-1546.
[http://dx.doi.org/10.1017/S0031182013000231] [PMID: 23552512]
[150]
Southgate, V.R. Schistosomiasis in the Senegal River Basin: before and after the construction of the dams at Diama, Senegal and Manantali, Mali and future prospects. J. Helminthol., 1997, 71(2), 125-132.
[http://dx.doi.org/10.1017/S0022149X00015790] [PMID: 9192711]
[151]
Stelma, F.F.; Sall, S.; Daff, B.; Sow, S.; Niang, M.; Gryseels, B. Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J. Infect. Dis., 1997, 176(1), 304-307.
[http://dx.doi.org/10.1086/517273] [PMID: 9207389]
[152]
Stelma, F.F.; Talla, I.; Sow, S.; Kongs, A.; Niang, M.; Polman, K.; Deelder, A.M.; Gryseels, B. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am. J. Trop. Med. Hyg., 1995, 53(2), 167-170.
[http://dx.doi.org/10.4269/ajtmh.1995.53.167] [PMID: 7677219]
[153]
Fallon, P.G.; Mubarak, J.S.; Fookes, R.E.; Niang, M.; Butterworth, A.E.; Sturrock, R.F.; Doenhoff, M.J. Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates. Exp. Parasitol., 1997, 86(1), 29-36.
[http://dx.doi.org/10.1006/expr.1997.4149] [PMID: 9149238]
[154]
Ismail, M.; Metwally, A.; Farghaly, A.; Bruce, J.; Tao, L.F.; Bennett, J.L. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am. J. Trop. Med. Hyg., 1996, 55(2), 214-218.
[http://dx.doi.org/10.4269/ajtmh.1996.55.214] [PMID: 8780463]
[155]
Ismail, M.; Botros, S.; Metwally, A.; William, S.; Farghally, A.; Tao, L.F.; Day, T.A.; Bennett, J.L. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am. J. Trop. Med. Hyg., 1999, 60(6), 932-935.
[http://dx.doi.org/10.4269/ajtmh.1999.60.932] [PMID: 10403323]
[156]
William, S.; Sabra, A.; Ramzy, F.; Mousa, M.; Demerdash, Z.; Bennett, J.L.; Day, T.A.; Botros, S. Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. Int. J. Parasitol., 2001, 31(10), 1093-1100.
[http://dx.doi.org/10.1016/S0020-7519(01)00215-6] [PMID: 11429173]
[157]
Sabra, A.N.; Botros, S.S. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure. J. Parasitol., 2008, 94(2), 537-541.
[http://dx.doi.org/10.1645/GE-1297.1] [PMID: 18564758]
[158]
Pica-Mattoccia, L.; Dias, L.C.; Moroni, R.; Cioli, D. Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene. Exp. Parasitol., 1993, 77(4), 445-449.
[http://dx.doi.org/10.1006/expr.1993.1104] [PMID: 8253157]
[159]
Pica-Mattoccia, L.; Doenhoff, M.J.; Valle, C.; Basso, A.; Troiani, A.R.; Liberti, P.; Festucci, A.; Guidi, A.; Cioli, D. Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni. Acta Trop., 2009, 111(1), 82-85.
[http://dx.doi.org/10.1016/j.actatropica.2009.01.012] [PMID: 19426668]
[160]
Liang, Y.S.; Dai, J.R.; Zhu, Y.C.; Coles, G.C.; Doenhoff, M.J. Genetic analysis of praziquantel resistance in Schistosoma mansoni. Southeast Asian J. Trop. Med. Public Health, 2003, 34(2), 274-280.
[PMID: 12971549]
[161]
Hines-Kay, J.; Cupit, P.M.; Sanchez, M.C.; Rosenberg, G.H.; Hanelt, B.; Cunningham, C. Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro. Mol. Biochem. Parasitol., 2012, 186(2), 87-94.
[http://dx.doi.org/10.1016/j.molbiopara.2012.09.006] [PMID: 23022771]
[162]
Ronketti, F.; Ramana, A.V.; Chao-Ming, X.; Pica-Mattoccia, L.; Cioli, D.; Todd, M.H. Praziquantel derivatives I: Modification of the aromatic ring. Bioorg. Med. Chem. Lett., 2007, 17(15), 4154-4157.
[http://dx.doi.org/10.1016/j.bmcl.2007.05.063] [PMID: 17555960]
[163]
Duan, W.W.; Qiu, S.J.; Zhao, Y.; Sun, H.; Qiao, C.; Xia, C.M. Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum. Bioorg. Med. Chem. Lett., 2012, 22(4), 1587-1590.
[http://dx.doi.org/10.1016/j.bmcl.2011.12.133] [PMID: 22264473]
[164]
Utzinger, J.; Xiao, S.H.; Tanner, M.; Keiser, J. Artemisinins for schistosomiasis and beyond. Currunt opinion in investigational drugs; London, England, 2007, 8(2), 105-116.
[PMID: 17328226]
[165]
Utzinger, J.; Xiao, S.; Keiser, J.; Chen, M.; Zheng, J.; Tanner, M. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr. Med. Chem., 2001, 8(15), 1841-1860.
[http://dx.doi.org/10.2174/0929867013371581] [PMID: 11772354]
[166]
Frère, J.M. Beta-lactamases and bacterial resistance to antibiotics. Mol. Microbiol., 1995, 16(3), 385-395.
[http://dx.doi.org/10.1111/j.1365-2958.1995.tb02404.x] [PMID: 7565100]
[167]
Cannatella, D.C.; De Sa, R.O. Xenopus laevis as a model organism. Syst. Biol., 1993, 42(4), 476-507.
[http://dx.doi.org/10.1093/sysbio/42.4.476]
[168]
Norcliffe, J.L.; Alvarez-Ruiz, E.; Martin-Plaza, J.J.; Steel, P.G.; Denny, P.W. The utility of yeast as a tool for cell-based, target-directed high-throughput screening. Parasitology, 2014, 141(1), 8-16.
[http://dx.doi.org/10.1017/S0031182013000425] [PMID: 23611102]
[169]
Sulbarán, G.; Alamo, L.; Pinto, A.; Márquez, G.; Méndez, F.; Padrón, R.; Craig, R. An invertebrate smooth muscle with striated muscle myosin filaments. Proc. Natl. Acad. Sci. USA, 2015, 112(42), E5660-E5668.
[http://dx.doi.org/10.1073/pnas.1513439112] [PMID: 26443857]
[170]
Berridge, M.J.; Lipp, P.; Bootman, M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol., 2000, 1(1), 11-21.
[http://dx.doi.org/10.1038/35036035] [PMID: 11413485]
[171]
Wolstenholme, A.J. Ion channels and receptor as targets for the control of parasitic nematodes. Int. J. Parasitol. Drugs Drug Resist., 2011, 1(1), 2-13.
[http://dx.doi.org/10.1016/j.ijpddr.2011.09.003] [PMID: 24533259]
[172]
Hurley, L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer, 2002, 2(3), 188-200.
[http://dx.doi.org/10.1038/nrc749] [PMID: 11990855]
[173]
Davis, A. Comparative trials of antimonial drugs in urinary schistosomiasis. Bull. World Health Organ., 1968, 38(2), 197-227.
[PMID: 5302298]
[174]
Bueding, E.; Mansour, J.M. The relationship between inhibition of phosphofructokinase activity and the mode of action of trivalent organic antimonials on Schistosoma mansoni. Br. J. Pharmacol. Chemother., 1957, 12(2), 159-165.
[http://dx.doi.org/10.1111/j.1476-5381.1957.tb00114.x] [PMID: 13446367]
[175]
Su, J.G.; Mansour, J.M.; Mansour, T.E. Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni. Mol. Biochem. Parasitol., 1996, 81(2), 171-178.
[http://dx.doi.org/10.1016/0166-6851(96)02702-8] [PMID: 8898332]
[176]
Schulman, M.D.; Ostlind, D.A.; Valentino, D. Mechanism of action of MK-401 against Fasciola hepatica: inhibition of phosphoglycerate kinase. Mol. Biochem. Parasitol., 1982, 5(3), 133-145.
[http://dx.doi.org/10.1016/0166-6851(82)90016-0] [PMID: 7088033]
[177]
Schulman, M.D.; Valentino, D. Fasciola hepatica: effect of 4-amino-6-trichloroethenyl-1,3-benzenedisulfonamide on glycolysis in vitro. Exp. Parasitol., 1980, 49(2), 206-215.
[http://dx.doi.org/10.1016/0014-4894(80)90117-4] [PMID: 6244978]
[178]
Schulman, M.D.; Valentino, D. Purification, characterization and inhibition by MK-401 of Fasciola hepatica phosphoglyceromutase. Mol. Biochem. Parasitol., 1982, 5(5), 321-332.
[http://dx.doi.org/10.1016/0166-6851(82)90039-1] [PMID: 6285191]
[179]
Mossallam, S.F.; Ali, S.M.; El Zawawy, L.A.; Said, D.E. The efficacy of antihelminthic compound; Clorsulon against experimental Schistosoma mansoni infection. J. Egypt. Soc. Parasitol., 2007, 37(1), 171-188.
[PMID: 17580576]
[180]
Shames, N.; Agrawal, M.; Rao, K. Chemotherapeutic efficacy of praziquantel and closantel in experimental porcine schistosomiasis. Indian J. Anim. Sci., 2000, 70(8), 797-800.
[181]
Timson, D.J. Metabolic enzymes of helminth parasites: potential as drug targets. Curr. Protein Pept. Sci., 2016, 17(3), 280-295.
[http://dx.doi.org/10.2174/1389203717999160226180733] [PMID: 26983888]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 5
Year: 2020
Page: [676 - 696]
Pages: 21
DOI: 10.2174/0929867325666180926145537
Price: $65

Article Metrics

PDF: 40
HTML: 3